MACROGENICS INC (MGNX)
$4.10+$0.02 (+0.49%) Today
Latest MGNX Insider Trades
Jeffrey Stuart Peters - OfficerOpen-market sale$129K
Jeffrey Stuart Peters - Officer
William K. Heiden - DirectorWilliam K. Heiden - DirectorMacrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 1 | 31,105 | $129K |
| Option exercise | 2 | 80,000 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
41 Form 4 filings on record, the earliest from Oct 9, 2024, newest first. Filing history page 2 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Eric Blasius Risser - Officer | Grant or award | Employee Stock Option (right to buy) | 550,000 | $0.00 | - | |
| Meenu Chhabra - Director | Option exercise | Common Stock | 6,500 | - | - | |
| Meenu Chhabra - Director | Option exercise | Restricted Stock Unit | 6,500 | $0.00 | - | |
| Meenu Chhabra - Director | Grant or award | Restricted Stock Unit | 3,750 | $0.00 | - | |
| Meenu Chhabra - Director | Grant or award | Stock Option (right to buy) | 22,000 | $0.00 | - | |
| Meenu Chhabra - Director | Grant or award | Stock Option (right to buy) | 49,213 | $1.27 | $63K | |
| Scott Thomas Jackson - Director | Option exercise | Common Stock | 6,500 | - | - | |
| Scott Thomas Jackson - Director | Option exercise | Restricted Stock Unit | 6,500 | $0.00 | - | |
| Scott Thomas Jackson - Director | Grant or award | Restricted Stock Unit | 3,750 | $0.00 | - | |
| Scott Thomas Jackson - Director | Grant or award | Stock Option (right to buy) | 22,000 | $0.00 | - | |
| Federica F. O'Brien - Director | Option exercise | Common Stock | 6,500 | - | - | |
| Federica F. O'Brien - Director | Option exercise | Restricted Stock Unit | 6,500 | $0.00 | - | |
| Federica F. O'Brien - Director | Grant or award | Restricted Stock Unit | 3,750 | $0.00 | - | |
| Federica F. O'Brien - Director | Grant or award | Stock Option (right to buy) | 22,000 | $0.00 | - | |
| Federica F. O'Brien - Director | Grant or award | Stock Option (right to buy) | 64,961 | $1.27 | $83K | |
| Karen Jean Ferrante - Director | Option exercise | Common Stock | 6,500 | - | - | |
| Karen Jean Ferrante - Director | Option exercise | Restricted Stock Unit | 6,500 | $0.00 | - | |
| Karen Jean Ferrante - Director | Grant or award | Restricted Stock Unit | 3,750 | $0.00 | - | |
| Karen Jean Ferrante - Director | Grant or award | Stock Option (right to buy) | 22,000 | $0.00 | - | |
| Edward Hurwitz - Director | Option exercise | Common Stock | 6,500 | - | - | |
| Edward Hurwitz - Director | Option exercise | Restricted Stock Unit | 6,500 | $0.00 | - | |
| Edward Hurwitz - Director | Grant or award | Restricted Stock Unit | 3,750 | $0.00 | - | |
| Edward Hurwitz - Director | Grant or award | Stock Option (right to buy) | 22,000 | $0.00 | - | |
| William K. Heiden - Director | Option exercise | Common Stock | 6,500 | - | - | |
| William K. Heiden - Director | Option exercise | Restricted Stock Unit | 6,500 | $0.00 | - | |
| William K. Heiden - Director | Grant or award | Restricted Stock Unit | 3,750 | $0.00 | - | |
| William K. Heiden - Director | Grant or award | Stock Option (right to buy) | 22,000 | $0.00 | - | |
| David C. Stump - Director | Option exercise | Common Stock | 6,500 | - | - | |
| David C. Stump - Director | Option exercise | Restricted Stock Unit | 6,500 | $0.00 | - | |
| David C. Stump - Director | Grant or award | Restricted Stock Unit | 3,750 | $0.00 | - | |
| David C. Stump - Director | Grant or award | Stock Option (right to buy) | 22,000 | $0.00 | - | |
| Jay Philip Siegel - Director | Option exercise | Common Stock | 6,500 | - | - | |
| Jay Philip Siegel - Director | Option exercise | Restricted Stock Unit | 6,500 | $0.00 | - | |
| Jay Philip Siegel - Director | Grant or award | Restricted Stock Unit | 3,750 | $0.00 | - | |
| Jay Philip Siegel - Director | Grant or award | Stock Option (right to buy) | 22,000 | $0.00 | - | |
| Margaret Liu - Director | Option exercise | Common Stock | 6,500 | - | - | |
| Margaret Liu - Director | Option exercise | Restricted Stock Unit | 6,500 | $0.00 | - | |
| Margaret Liu - Director | Grant or award | Restricted Stock Unit | 3,750 | $0.00 | - | |
| Margaret Liu - Director | Grant or award | Stock Option (right to buy) | 22,000 | $0.00 | - | |
 Scott Koenig - Officer | Gift | Common Stock | 53,265 | - | - | |
| Scott Koenig - Officer | Gift | Common Stock | 53,265 | - | - |
A Form 144 is notice of an INTENDED sale, not a completed one. It often precedes the Form 4 that reports the trade actually happening.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| Jeffrey Peters | Officer | 31,105 | $129K | View on EDGAR | |
| Jay Siegel | Former Director | 42,080 | $176K | View on EDGAR | |
| Jay Siegel | Former Director | 34,916 | $131K | View on EDGAR |
MACROGENICS INC (MGNX) had 2 insider filings in the last 90 days, with the most recent on 2026-08-20. The full record for MGNX runs to 41 Form 4 filings, the earliest from 2024-10-09. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of MGNX were filed in the last 90 days. 2 purchases are on record for this company.
1 insider sale of MGNX was filed in the last 90 days, totaling $129K.
This page tracks MGNX Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add MGNX to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
$MGRMMonogram Technologies Inc.
$MGRXMANGOCEUTICALS, INC.
$MGTXMeiraGTx Holdings plc
$MGXMetagenomi Therapeutics, Inc.
$MIRAMIRA PHARMACEUTICALS, INC.
$MIRMMirum Pharmaceuticals, Inc.
$MISTMilestone Pharmaceuticals Inc.
$MLSSMILESTONE SCIENTIFIC INC.
$MLTXMoonLake Immunotherapeutics
$MLYSMineralys Therapeutics, Inc.Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
